CN104288775A - 用于药物用途的neurturin缀合物 - Google Patents

用于药物用途的neurturin缀合物 Download PDF

Info

Publication number
CN104288775A
CN104288775A CN201410282849.2A CN201410282849A CN104288775A CN 104288775 A CN104288775 A CN 104288775A CN 201410282849 A CN201410282849 A CN 201410282849A CN 104288775 A CN104288775 A CN 104288775A
Authority
CN
China
Prior art keywords
neurturin
amino acid
variant
conjugate
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410282849.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·奥斯滕
M·格泽
R·穆斯曼
F·哈德
T·西格蒙德
M·施奈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Publication of CN104288775A publication Critical patent/CN104288775A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201410282849.2A 2007-11-05 2008-11-05 用于药物用途的neurturin缀合物 Pending CN104288775A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07021493 2007-11-05
EP07021493.7 2007-11-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880114325.5A Division CN101848735B (zh) 2007-11-05 2008-11-05 用于药物用途的neurturin缀合物

Publications (1)

Publication Number Publication Date
CN104288775A true CN104288775A (zh) 2015-01-21

Family

ID=40521395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410282849.2A Pending CN104288775A (zh) 2007-11-05 2008-11-05 用于药物用途的neurturin缀合物
CN200880114325.5A Expired - Fee Related CN101848735B (zh) 2007-11-05 2008-11-05 用于药物用途的neurturin缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880114325.5A Expired - Fee Related CN101848735B (zh) 2007-11-05 2008-11-05 用于药物用途的neurturin缀合物

Country Status (17)

Country Link
US (3) US9029323B2 (enExample)
EP (1) EP2217282A2 (enExample)
JP (2) JP2011503019A (enExample)
KR (2) KR20150139982A (enExample)
CN (2) CN104288775A (enExample)
AU (1) AU2008324426B2 (enExample)
BR (1) BRPI0819220A2 (enExample)
CA (1) CA2742839A1 (enExample)
CO (1) CO6280503A2 (enExample)
CR (1) CR11406A (enExample)
EA (1) EA201070484A1 (enExample)
IL (1) IL205290A (enExample)
MX (1) MX2010004899A (enExample)
NZ (1) NZ585262A (enExample)
SG (1) SG185946A1 (enExample)
WO (1) WO2009059755A2 (enExample)
ZA (1) ZA201003227B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222070A1 (en) 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
DK1694354T3 (da) 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
BR112012009801A8 (pt) * 2009-10-30 2016-08-30 Cns Therapeutics Inc Polipeptídeo neurturina e variante de neurturina
US9127083B2 (en) 2009-10-30 2015-09-08 Ntf Therapeutics, Inc. Neurturin molecules
US8445432B2 (en) 2009-10-30 2013-05-21 Ntf Therapeutics Inc Neurturin molecules
US8742677B2 (en) * 2010-01-11 2014-06-03 System General Corp. LED drive circuit with a programmable input for LED lighting
CN102453725B (zh) * 2010-11-02 2014-06-11 杭州纽龙生物科技有限公司 一种重组载体、包含该重组载体的重组菌株及制备方法
JP6051378B2 (ja) * 2011-05-02 2016-12-27 国立大学法人 熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
JP2003524381A (ja) * 1998-09-22 2003-08-19 ユニヴァーシティ オブ メリーランド，ボルチモア システインノット成長因子ミュータント
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
EP2275118A3 (en) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Pancreas-specific proteins
ES2342397T3 (es) * 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
DK1694354T3 (da) * 2003-11-27 2009-10-26 Develogen Ag Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
EP1872790A1 (en) * 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin

Also Published As

Publication number Publication date
EP2217282A2 (en) 2010-08-18
IL205290A (en) 2014-01-30
WO2009059755A2 (en) 2009-05-14
BRPI0819220A2 (pt) 2019-02-26
CR11406A (es) 2010-10-25
US20130231283A1 (en) 2013-09-05
US20160060317A1 (en) 2016-03-03
CN101848735A (zh) 2010-09-29
JP2015057384A (ja) 2015-03-26
ZA201003227B (en) 2011-03-30
US20110003741A1 (en) 2011-01-06
CO6280503A2 (es) 2011-05-20
MX2010004899A (es) 2010-09-07
JP2011503019A (ja) 2011-01-27
KR20100098619A (ko) 2010-09-08
KR20150139982A (ko) 2015-12-14
SG185946A1 (en) 2012-12-28
US9029323B2 (en) 2015-05-12
AU2008324426B2 (en) 2014-03-27
NZ585262A (en) 2012-06-29
EA201070484A1 (ru) 2011-04-29
CA2742839A1 (en) 2009-05-14
AU2008324426A1 (en) 2009-05-14
IL205290A0 (en) 2010-12-30
WO2009059755A3 (en) 2009-09-24
CN101848735B (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
CN101848735B (zh) 用于药物用途的neurturin缀合物
EP1881850B1 (en) Glp-1 pegylated compounds
JP5688969B2 (ja) プロテアーゼに対して安定しているペグ化インスリンアナログ
CN101870728A (zh) 新型Exendin变体及其缀合物
BRPI0715943A2 (pt) mÉtodo para a produÇço de conjugados de fator de crescimento semelhante À insulina-1 e poli(etileno glicol)
AU2014236728B2 (en) Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
Tomono et al. Nasal absorption enhancement of protein drugs independent to their chemical properties in the presence of hyaluronic acid modified with tetraglycine-L-octaarginine
AU2009246851B2 (en) Conjugates of a cholinesterase moiety and a polymer
US11098104B2 (en) Pegylated endostatin analogue and application thereof
AU2017246404A1 (en) Conjugated C1 esterase inhibitor and uses thereof
US20140162948A1 (en) Formulation for increasing bioavailability of neurturin
Liu et al. Chemical synthesis and characterization of a nonfibrillating glycoglucagon
KR20220125289A (ko) Fgf-21 접합체 제제
CN104447981B (zh) 端羟基聚乙二醇化的人胰岛素及其类似物的偶联物
AU2014362992A1 (en) A process for preparing a composition of pegylated proteins
CN119080909A (zh) 负载peg-epo及间充质干细胞的组合物、药物及其制备方法
KR20040066712A (ko) 인간 성장 호르몬의 결합체

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150121

WD01 Invention patent application deemed withdrawn after publication